GlassScriptPhysician profile
Huijian J Wang
NPI 1043488661
$15,693.98
in general payments reported to CMS, 2019-2025
40 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $639 · 2021: $1,151 · 2022: $6,166 · 2023: $1,846 · 2024: $2,974 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,160 · Travel and Lodging: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,160.21 |
| Travel and Lodging | $439.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $4,039.40 | 2019-2024 | Biomonitor |
| Abbott Laboratories | $1,954.90 | 2019-2025 | Ensite Precision, Tacticath Ablation Catheter, Sensor Enabled, Amplatzer Amulet |
| Biosense Webster, INC. | $1,781.66 | 2019-2025 | Carto 3, Nuvision Ice Catheter, Na |
| Zoll Respicardia, INC. | $1,255.65 | 2022 | |
| Boston Scientific Corporation | $869.05 | 2019-2025 | Accolade Sr, General - Tachy, Lux-Dx Insertable Cardiac Monitor |
| Novartis Pharmaceuticals Corporation | $622.16 | 2019-2025 | |
| Medtronic, INC. | $534.91 | 2021-2025 | Evera Mri Xt Dr Surescan, Micra, Linq II |
| Janssen Pharmaceuticals, INC | $498.82 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $385.03 | 2022-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $376.85 | 2021-2025 | Optimizer, Optimizer |
| Cvrx, INC. | $370.64 | 2021-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $348.87 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.06 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $275.53 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $214.50 | 2021-2025 | Farxiga |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $210.30 | 2019-2025 | |
| Atricure, INC. | $208.17 | 2021-2025 | Atriclip Laa Exclusion System, Epi-Ease Epicardial Access System, Epi-Sense Guided Coagulation System With Visitrax |
| Novo Nordisk INC | $177.48 | 2023-2025 | Wegovy, Ozempic |
| Edwards Lifesciences Corporation | $163.14 | 2022-2023 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.11 | 2021-2025 | Lifevest |
| Medtronic Vascular, INC. | $132.39 | 2019-2020 | |
| Cordis US Corp. | $99.87 | 2022 | |
| Lundbeck LLC | $87.16 | 2019-2021 | |
| Inspire Medical Systems, INC. | $79.33 | 2024 | Inspire |
| Abiomed | $78.49 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $57.80 | 2023 | Arcalyst |
| Acutus Medical, INC. | $43.12 | 2020-2022 | |
| Cardiovascular Systems INC. | $40.92 | 2019-2022 | |
| Elutia, INC. | $38.12 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $36.97 | 2025 | |
| Arbor Pharmaceuticals, INC. | $34.00 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $31.39 | 2024 | Arcalyst |
| Philips North America LLC | $30.73 | 2024 | (Ck4) Mcot |
| Bayer Healthcare Pharmaceuticals INC. | $27.37 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $25.35 | 2023 | Inpefa |
| Convatec INC. | $20.03 | 2024 | |
| Esperion Therapeutics, INC. | $16.38 | 2025 | Nexletol |
| Irhythm Technologies, INC. | $16.06 | 2024 | Zio Xt Patch, Zio Monitor |
| Cardiva Medical, INC. | $15.27 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huijian Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.